VPIM
RXRX icon

Vanguard Personalized Indexing Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
33,864
+23,286
+220% +$90K ﹤0.01% 1945
2025
Q4 		$43.3K Sell
10,578
-678
-6% -$3.36K ﹤0.01% 1897
2025
Q3 		$54.9K Sell
11,256
-897
-7% -$4.71K ﹤0.01% 1893
2025
Q2 		$61.5K Sell
12,153
-2,570
-17% -$12.6K ﹤0.01% 1801
2025
Q1 		$77.9K Buy
14,723
+3,284
+29% +$23.9K ﹤0.01% 1645
2024
Q4 		$77.3K Buy
+11,439
New +$76.9K ﹤0.01% 1645

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Personalized Indexing Management's RXRX Position: Q1 2026 in Review

Vanguard Personalized Indexing Management increased its Recursion Pharmaceuticals (RXRX) stake by 220% in Q1 2026, buying an estimated $90K and bringing the position to 33,864 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Vanguard Personalized Indexing Management first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Vanguard Personalized Indexing Management held 33,864 shares of Recursion Pharmaceuticals worth $104K as of Q1 2026.
  • Vanguard Personalized Indexing Management bought 23,286 Recursion Pharmaceuticals shares in Q1 2026, an estimated $90K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #1945 holding.
  • Vanguard Personalized Indexing Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.